Literature DB >> 29251647

Pretreatment 18F-Fluorodeoxyglucose Positron Emission Tomography Standardized Uptake Values and Tumor Size in Medically Inoperable Nonsmall Cell Lung Cancer Is Prognostic of Overall 2-Year Survival After Stereotactic Body Radiation Therapy.

Madison R Kocher, Anand Sharma, Elizabeth Garrett-Mayer, James G Ravenel.   

Abstract

OBJECTIVE: The aim of this study was to determine prognostic value of tumor size and metabolic activity on survival for patients with early stage nonsmall cell lung cancer receiving stereotactic body radiation therapy.
METHODS: We retrospectively evaluated the patients who underwent positron emission tomography-computed tomography scan before stereotactic body radiation therapy treatment. Tumor diameter, tumor volume, maximum standardized uptake value (SUVmax), standardized uptake value (SUV) average, and SUV volume were obtained. Cox regression analyses were performed to determine the associations between tumor characteristics and survival.
RESULTS: The patients with large tumors and high SUVmax have worse survival than patients with small tumors and low SUVmax (hazard ratio [HR] = 3.47, P = 0.007). Patients with small tumors and high SUVmax (HR = 1.80; P = 0.24) and large tumors and low SUVmax (HR = 1.55; P = 0.43) had increased risk of death compared with patients with small tumors and low SUVmax.
CONCLUSIONS: Both increased tumor size and metabolic activity are associated with increased risk of death. Combining size and metabolic activity together is superior for predicting 2-year survival and identifying patients for whom survival is statistically worse.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29251647      PMCID: PMC5764806          DOI: 10.1097/RCT.0000000000000653

Source DB:  PubMed          Journal:  J Comput Assist Tomogr        ISSN: 0363-8715            Impact factor:   1.826


  18 in total

1.  Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis.

Authors:  Sashendra Senthi; Frank J Lagerwaard; Cornelis J A Haasbeek; Ben J Slotman; Suresh Senan
Journal:  Lancet Oncol       Date:  2012-06-22       Impact factor: 41.316

2.  Volume-based parameters measured by using FDG PET/CT in patients with stage I NSCLC treated with stereotactic body radiation therapy: prognostic value.

Authors:  Yoko Satoh; Hiroshi Onishi; Atsushi Nambu; Tsutomu Araki
Journal:  Radiology       Date:  2013-10-28       Impact factor: 11.105

3.  Formula corrected maximal standardized uptake value in FDG-PET for partial volume effect and motion artifact is not a prognostic factor in stage I non-small cell lung cancer treated with stereotactic body radiotherapy.

Authors:  Takaya Yamamoto; Noriyuki Kadoya; Yuko Shirata; Tomohiro Kaneta; Masashi Koto; Rei Umezawa; Youjirou Ishikawa; Masaki Kubozono; Toshiyuki Sugawara; Haruo Matsushita; Keiko Abe; Ken Takeda; Keiichi Jingu
Journal:  Ann Nucl Med       Date:  2015-06-04       Impact factor: 2.668

4.  FDG Uptake on Positron Emission Tomography Correlates with Survival and Time to Recurrence in Patients with Stage I Non-Small-Cell Lung Cancer.

Authors:  Woocheol Kwon; Brandon A Howard; James E Herndon; Edward F Patz
Journal:  J Thorac Oncol       Date:  2015-06       Impact factor: 15.609

5.  Prognostic value of total lesion glycolysis by 18F-FDG PET/CT in surgically resected stage IA non-small cell lung cancer.

Authors:  Seong Yong Park; Arthur Cho; Woo Sik Yu; Chang Young Lee; Jin Gu Lee; Dae Joon Kim; Kyung Young Chung
Journal:  J Nucl Med       Date:  2014-12-18       Impact factor: 10.057

6.  Incidental prophylactic nodal irradiation and patterns of nodal relapse in inoperable early stage NSCLC patients treated with SBRT: a case-matched analysis.

Authors:  Louis Lao; Andrew J Hope; Manjula Maganti; Anthony Brade; Andrea Bezjak; Elantholi P Saibishkumar; Meredith Giuliani; Alexander Sun; B C John Cho
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-07-03       Impact factor: 7.038

Review 7.  Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project.

Authors:  Thierry Berghmans; Michèle Dusart; Marianne Paesmans; Claude Hossein-Foucher; Irene Buvat; Catherine Castaigne; Arnaud Scherpereel; Céline Mascaux; Michel Moreau; Martine Roelandts; Stéphane Alard; Anne-Pascale Meert; Edward F Patz; Jean-Jacques Lafitte; Jean-Paul Sculier
Journal:  J Thorac Oncol       Date:  2008-01       Impact factor: 15.609

8.  Maximum standardized uptake value on FDG-PET is a strong predictor of overall and disease-free survival for non-small-cell lung cancer patients after stereotactic body radiotherapy.

Authors:  Atsuya Takeda; Naoko Sanuki; Hirofumi Fujii; Noriko Yokosuka; Shuichi Nishimura; Yousuke Aoki; Yohei Oku; Yukihiko Ozawa; Etsuo Kunieda
Journal:  J Thorac Oncol       Date:  2014-01       Impact factor: 15.609

9.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

10.  Pretreatment SUVmax predicts progression-free survival in early-stage non-small cell lung cancer treated with stereotactic body radiation therapy.

Authors:  Zachary D Horne; David A Clump; John A Vargo; Samir Shah; Sushil Beriwal; Steven A Burton; Annette E Quinn; Matthew J Schuchert; Rodney J Landreneau; Neil A Christie; James D Luketich; Dwight E Heron
Journal:  Radiat Oncol       Date:  2014-01-30       Impact factor: 3.481

View more
  1 in total

1.  Usefulness of Hybrid PET/MRI in Clinical Evaluation of Head and Neck Cancer Patients.

Authors:  Natalia Samolyk-Kogaczewska; Ewa Sierko; Dorota Dziemianczyk-Pakiela; Klaudia Beata Nowaszewska; Malgorzata Lukasik; Joanna Reszec
Journal:  Cancers (Basel)       Date:  2020-02-22       Impact factor: 6.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.